Squar Milner Financial Services LLC Has $102,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Squar Milner Financial Services LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 61.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,507 shares of the biopharmaceutical company’s stock after selling 2,400 shares during the quarter. Squar Milner Financial Services LLC’s holdings in Gilead Sciences were worth $102,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Nelson Roberts Investment Advisors LLC raised its holdings in Gilead Sciences by 1.1% in the 2nd quarter. Nelson Roberts Investment Advisors LLC now owns 70,467 shares of the biopharmaceutical company’s stock valued at $4,761,000 after buying an additional 785 shares during the last quarter. Brookstone Capital Management bought a new position in Gilead Sciences in the 2nd quarter valued at approximately $2,331,000. Manning & Napier Group LLC raised its holdings in Gilead Sciences by 18.4% in the 2nd quarter. Manning & Napier Group LLC now owns 404,397 shares of the biopharmaceutical company’s stock valued at $27,320,000 after buying an additional 62,980 shares during the last quarter. Artemis Investment Management LLP raised its holdings in Gilead Sciences by 0.8% in the 2nd quarter. Artemis Investment Management LLP now owns 271,086 shares of the biopharmaceutical company’s stock valued at $18,296,000 after buying an additional 2,135 shares during the last quarter. Finally, Zeke Capital Advisors LLC raised its holdings in Gilead Sciences by 3.5% in the 2nd quarter. Zeke Capital Advisors LLC now owns 23,186 shares of the biopharmaceutical company’s stock valued at $1,566,000 after buying an additional 775 shares during the last quarter. Institutional investors and hedge funds own 78.87% of the company’s stock.

A number of brokerages recently issued reports on GILD. Royal Bank of Canada upgraded shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price objective for the company in a report on Monday, July 29th. Credit Suisse Group lowered their price target on shares of Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating for the company in a report on Wednesday, July 31st. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Friday, July 12th. Finally, Cantor Fitzgerald set a $88.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $82.29.

Shares of NASDAQ:GILD traded down $0.46 during mid-day trading on Wednesday, hitting $63.52. The company had a trading volume of 108,866 shares, compared to its average volume of 6,154,606. The company has a fifty day moving average of $67.02. The firm has a market capitalization of $82.80 billion, a P/E ratio of 10.35, a PEG ratio of 3.09 and a beta of 1.16. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.85 and a quick ratio of 3.75. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.14. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. Gilead Sciences’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.91 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, September 12th. This represents a $2.52 annualized dividend and a dividend yield of 3.97%. Gilead Sciences’s dividend payout ratio is currently 40.98%.

In other news, EVP Brett A. Pletcher sold 5,816 shares of Gilead Sciences stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total value of $399,850.00. Following the completion of the sale, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,869,862.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 7,200 shares of Gilead Sciences stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: Trading on Margin

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.